Department of Nutrition and Dietetics, Faculty of Health Science, Avrasya University, Trabzon, Turkey.
Pathologist, Histologist and Embryologist Faculty of Health Science, Avrasya University, Trabzon, Turkey.
Vaccine. 2023 Apr 24;41(17):2860-2867. doi: 10.1016/j.vaccine.2023.03.046. Epub 2023 Mar 27.
Immune levels were observed by giving vitamin D supplements to vitamin D deficient women who received the COVID-19 vaccine.
In the research, there were volunteer women who had received two doses of the COVID-19 vaccine who participated for a mean of more than 65 days. Group D (n=14 Pfizer-BioNTech, 2 Sinovac) received 150,000 IU of vitamin D supplementation, but group C (n=14 Pfizer-BioNTech), 3 Sinovac) no support was provided.
When the consumption of vitamin D ends (D group), serum 25-Hydroxy Vitamin D levels were found to increase regularly in the (W3) last measurements (p=0.001). There was no significant difference in immunoglobulin M levels between groups D and C (Control group) (p=0.063). It was observed that the immunoglobulin G levels reached the peak level between the W1 and W2 measurements of the D group (P<0.001) and there were significant differences between the three sizes. Also, no correlation was found between the D group's initial serum immunoglobulin G and 25-Hydroxy Vitamin D levels. However, when the final measurements were examined, a significant positive correlation was found between immunoglobulin G and 25-Hydroxy Vitamin D levels (r=0.558, p=0.031).
It was determined that serum IgG levels increased significantly depending on the duration between those who used vitamin D and those who did not and it was above the initial level for a long time. A positive and significant relationship was found between the last measured immunoglobulin G and 25(OH) D levels while vitamin D supplementation continued.
This study registered under ClinicalTrials.gov (Identifier no. NCT05447065).
给维生素 D 缺乏的接受 COVID-19 疫苗的女性补充维生素 D，观察免疫水平。
在这项研究中，有 14 名接受过两剂 COVID-19 疫苗的志愿者女性参与，平均时间超过 65 天。D 组（n=14 Pfizer-BioNTech，2 Sinovac）接受 150,000 IU 的维生素 D 补充剂，但 C 组（n=14 Pfizer-BioNTech，3 Sinovac）未提供支持。
当维生素 D 消耗结束时（D 组），（W3）最后一次测量时发现血清 25-羟维生素 D 水平定期增加（p=0.001）。D 组和 C 组（对照组）之间的免疫球蛋白 M 水平没有显著差异（p=0.063）。观察到 D 组的免疫球蛋白 G 水平在 W1 和 W2 测量之间达到峰值（P<0.001），并且三个尺寸之间存在显著差异。此外，D 组初始血清免疫球蛋白 G 与 25-羟维生素 D 水平之间没有相关性。然而，当检查最终测量值时，发现免疫球蛋白 G 与 25-羟维生素 D 水平之间存在显著正相关（r=0.558，p=0.031）。
确定使用维生素 D 的人与未使用维生素 D 的人之间的血清 IgG 水平随时间显著增加，并且长时间保持在初始水平之上。在继续进行维生素 D 补充的同时，发现最后测量的免疫球蛋白 G 与 25（OH）D 水平之间存在正显著关系。
本研究在 ClinicalTrials.gov（标识符号 NCT05447065）下注册。
